[Previous Months][Date Index][Thread Index][Join - Register][Login]
[Message Prev][Message Next][Thread Prev][Thread Next]

[IP] Disetronic Newsletter

What I thought was interesting in this is the latest report
on their "next generation" of pump, really their next
generation of infusion set.


DiaPort system undergoing clinical testing in Europe

Disetronic has developed a system that adds to the
advantages of insulin pump therapy. The system, named
DiaPort (pronounced "dye-a-port"), is a percutaneous port
system that allows insulin to be infused into the body where
it's most effective-close to the liver. Percutaneous means
"performed through the skin," which indicates the port is
accessible from the surface of the skin but delivers insulin

"The DiaPort allows people who have insulin dependent
diabetes to deliver insulin to the same location in the body
as a person without diabetes," says Jim Myers, Disetronic's
vice president of business development. "Presenting the
liver with a higher concentration of insulin in the blood
allows the liver to better process digested carbohydrates,
further increasing the benefits of insulin pump therapy."

DiaPort offers two different "routes" for delivering
insulin. One is through the umbilical vein, which will carry
the insulin closer to the liver. Using this route, the
insulin enters the liver in exactly the same area as the
insulin in a person without diabetes.

Another possible route to administer insulin through the
DiaPort is the peritoneal cavity, which is located between
the lower internal organs and the abdominal muscles. This
route also carries insulin to the liver, but the insulin
must first be absorbed through blood vessels.

Currently in Phase III clinical trials in Europe, the device
is expected to be introduced there in 1999. DiaPort is not
currently available in the United States, but Disetronic
anticipates U.S. clinical trials for the device should begin
within the next 12 months.

The DiaPort is designed to work with all Disetronic insulin
pumps. When the device becomes available, the only other
necessary component will be a specially designed infusion

According to Myers, DiaPort is Disetronic's alternative to
the implanted insulin pump. "Based on our research and other
research we've followed in Europe, implanted insulin pumps
don't provide the benefits necessary to justify the cost and
risk," says Myers. "The clinical benefits are limited and
the cost 'is high. The DiaPort, on the other hand, is
economical while providing pump users with ease of use and
excellent control."

Myers adds that he believes it is unlikely insurance
companies in this country would be willing to pick up the
costs associated with implanted pumps when a more clinically
effective and less costly alternative is available. He
explains that implanted pumps typically need a "battery
change" every three to four years, requiring surgery that
further adds costs and possible complications. Myers
anticipates coverage for the DiaPort, with an external pump,
is more likely since it should provide equal or better
clinical benefits and lower long-term costs than an
implanted pump.

For updates on this important medical achievement, be sure
to read future issues of this newsletter or visit
Insulin-Pumpers website http://www.bizsystems.com/Diabetes/